<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya</journal-id>
      <journal-id journal-id-type="publisher-id">.</journal-id>
      <journal-title>Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya</journal-title><issn pub-type="ppub">2621-4814</issn><issn pub-type="epub">2621-4814</issn><publisher>
      	<publisher-name>Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.33084/bjop.v3i1.1082</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group><subject>Molecular docking</subject><subject>Antiinflammatory activity</subject><subject>1,2,4-triazol-3-thiones</subject><subject>PASS</subject><subject>COX-2</subject></subj-group>
      </article-categories>
      <title-group>
        <article-title>Prediction of the Antiinflammatory Activity of New S-alkyl Derivatives of 1,2,4-triazol-3-thiones Using the PASS Computer Program and Molecular Docking</article-title><subtitle>Prediction of the Antiinflammatory Activity of New S-alkyl Derivatives of 1,2,4-triazol-3-thiones Using the PASS Computer Program and Molecular Docking</subtitle></title-group>
      <contrib-group><contrib contrib-type="author">
	<name name-style="western">
	<surname>Chalenko</surname>
		<given-names>Natalya Mykolaivna</given-names>
	</name>
	<aff>Kharkiv National Medical University, Kharkiv, Ukraine</aff>
	</contrib><contrib contrib-type="author">
	<name name-style="western">
	<surname>Syrovaya</surname>
		<given-names>Anna Olegovna</given-names>
	</name>
	<aff>Kharkiv National Medical University, Kharkiv, Ukraine</aff>
	</contrib><contrib contrib-type="author">
	<name name-style="western">
	<surname>Kobzar</surname>
		<given-names>Natalya P</given-names>
	</name>
	<aff>National University of Pharmacy, Kharkiv, Ukraine</aff>
	</contrib><contrib contrib-type="author">
	<name name-style="western">
	<surname>Rakhimova</surname>
		<given-names>Maryna V</given-names>
	</name>
	<aff>National University of Pharmacy, Kharkiv, Ukraine</aff>
	</contrib><contrib contrib-type="author">
	<name name-style="western">
	<surname>Sych</surname>
		<given-names>Irina A</given-names>
	</name>
	<aff>National University of Pharmacy, Kharkiv, Ukraine</aff>
	</contrib><contrib contrib-type="author">
	<name name-style="western">
	<surname>Sych</surname>
		<given-names>Igor Vladimirovich</given-names>
	</name>
	<aff>Hon. Prof. M. S. Bokarius Kharkiv Research Institute of Forensic Examinations, Kharkiv, Ukraine</aff>
	</contrib></contrib-group>		
      <pub-date pub-type="ppub">
        <month>02</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>27</day>
        <month>02</month>
        <year>2020</year>
      </pub-date>
      <volume>3</volume>
      <issue>1</issue>
      <permissions>
        <copyright-statement>© 2020 Natalya Mykolayivna Chalenko, Anna Olegovna Syrovaya, Natalya P Kobzar, Maryna V Rakhimova, Irina A Sych, Igor Vladimirovich Sych</copyright-statement>
        <copyright-year>2020</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-sa/4.0/"><p>This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.</p></license>
      </permissions>
      <related-article related-article-type="companion" vol="2" page="e235" id="RA1" ext-link-type="pmc">
			<article-title>Prediction of the Antiinflammatory Activity of New S-alkyl Derivatives of 1,2,4-triazol-3-thiones Using the PASS Computer Program and Molecular Docking</article-title>
      </related-article>
	  <abstract abstract-type="toc">
		<p>
			The strategy of rational approaches to the search for selective COX-2 inhibitors as potential antiinflammatory agents has been proposed and elaborated. It is based on the use of PASS-prediction and molecular docking. The choice of the basic structure of 4-amino-3-thio-1,2,4-triazole as a promising object of chemical modification has been substantiated. Using a modification of the primary molecule, a virtual library of S-derivatives of 5-substituted 4-amino(pyrrol)3-thio-4H-1,2,4-triazoles in the amount of 100 compounds (ten groups) has been obtained by introducing various pharmacophore fragments. Based on the analysis of the results of the PASS-prediction and molecular docking, six of the ten planned groups of compounds have been selected for the synthesis as promising selective COX-2 inhibitors. The reliability of the prediction results has already been confirmed for one of the promising group 4-amino-5-(pyridine-4-yl)-1,2,4-triazole (4Н)-3-yl-thioacetamides.
		</p>
		</abstract>
    </article-meta>
  </front>
  <body><sec>
			<title>INTRODUCTION</title>
				<p >The synthesis of new structures
with the predicted activity is expedient to carry out in that class of chemical
compounds where substances with a certain directed action have been already
found (Oliveira et al., 2019).
Scientists refer the heterocyclic system of 1,2,4-triazole to the privileged
structure (“privileged scaffold”), since most of the derivatives of this
heterocyclic synthesized exhibit some pharmacological activity, including the
antiinflammatory (Zhuang et al., 2017). The combination of factors
affecting biochemical processes, as well as the practical absence of toxic
effects on the body, indicates the feasibility of further targeted search for
new biologically active substances among derivatives of 1,2,4-triazole (Mioc et
al., 2017). A
careful study of the literature data on the spectrum of pharmacological
properties of the heterocyclic system of 1,2,4-triazole allows us to
confidently assert that the presence of this cycle in the structure of
substances determines the manifestation of the antiinflammatory activity (Moise et
al., 2009). Previous
research by Sondhi et al. (2007) obtained a large group of derivatives of
1,2,4-triazole, pyridine, pyrrol, and other related heterocyclic compounds,
among them selective cyclooxygenase-2 (COX-2), 5-lipoxygenase (5-LOX), and
COX-2/5-LOX double inhibitors were identified. Moreover, some studies suggest
that the presence of the 1,2,4-triazole cycle causes selective inhibition of
COX-2 (Cai et al., 2015; Jiang et
al., 2010).</p><p >In addition, 1,2,4-triazole
derivatives are low-toxic, rather simple in synthesis and highly reactive
substances. It allows to introduce various pharmacophore fragments into their
structure (Khanage et al., 2012).
Our analysis of the scientific literature has shown that despite a large number
of publications devoted to functional derivatives of 1,2,4-triazole the pharmacological
potential of this class of compounds at the present stage is not exhausted. </p><p >The compound of 4-amino-3-thio-1,2,4-triazole
has a high synthetic potential, significant opportunities in terms of the
introduction of pharmacophore fragments and, correspondingly, the expansion of
the spectrum for searching the biological activity. The presence of a sulfur
atom in the basic structure increases lipophilicity and, therefore, can improve
absorption and bioavailability of the compounds synthesized on its basis (Jin et al.,
2007). In
addition, thio and amino groups are reaction centers for the introduction of
additional pharmacophores into the molecule.</p>
			</sec><sec>
			<title>MATERIALS AND METHODS</title>
				<p >The introduction of different pharmacophore
fragments into the molecule by modifying the thio group and obtaining S-derivatives of 5-substituted
4-amino(pyrrol)3-thio-4H-1,2,4-triazoles (groups of compounds <bold>I</bold>-<bold>X</bold>).
This allows increasing the chances of finding new effective compounds in this
series, as presented in <bold>Figure 1</bold>. The following modification have been planned as follows:</p><p >1.
Alkylation of
5-pyridine-4-amino(pyrrol)3-thio-1,2,4- triazole derivatives by haloalkanes
(1-bromopropane, 1-bromohexane, 1-bromoheptan, 1-bromononane, 1-bromodecane) (<bold>I</bold>) in order to increase lipophilicity
of the initial 5-pyridine-4-yl-4-amino-3-thio-4Н-1,2,4-triazole.</p><p >2.
Introduction of the arylidene
aniline fragment (<bold>II</bold>) to alkyl
derivatives of group (<bold>I</bold>), it will
increase the number of unsaturated bonds in the molecule and may increase the
activity.</p><p >3.
Oxidation of 5-(pyridine-4)-4-amino-3-thio-1,2,4-triazole
derivatives to alkyl sulfonyl derivatives (<bold>III</bold>)
as in the structure of modern oxicams there is a sulfonyl group.</p><p >4.
Introduction of the
5-(pyridine-4)-4-amino-3-thio-1,2,4-triazole fragment of alkyl urea (<bold>IV</bold>) into the basic structure since
there are literature data concerning the effect of the acetamide residue the
increase of the antiinflammatory activity.</p><p >5.
Alkylation of
5-(pyridine-4(2,3))-4-amino-3-thio-1,2,4-triazoles (<bold>V</bold>-<bold>VI</bold>) by
α-chloroacetamide’s taking into account the literature data concerning the
effect of the acetamide residue on the increase of the antiinflammatory
activity.</p><p >6.
Alkylation of
5-(furyl-2)-amino-3-thio-1,2,4-triazoles (<bold>VII</bold>)
by α-chloroacetamide’s.</p><p >7.
Replacement of the amino group in S-alkyl derivatives of
5-(pyridine-2,4)-4-amino-3-thio-4Н-1,2,4-triazoles (<bold>VIII</bold>-<bold>IX</bold>) and
5-(furyl-2)-4-amino-3-thio-4Н-1,2,4-triazoles (<bold>X</bold>) on the pyrrol residue.</p><p ><bold>I</bold></p><p ></p><p >
 
</p><p ><bold>II</bold></p><p >
 
</p><p ><bold>III</bold></p><p ></p><p >
 
</p><p ><bold>IV</bold></p><p ></p><p >
 
</p><p >X=N, Y=C X=C, Y=N</p><p ><bold>V</bold></p><p ></p><p >
 
</p><p ><bold>VI</bold></p><p ></p><p >
 
</p><p ><bold>VII</bold></p><p ></p><p >
 
</p><p ><bold>VIII</bold></p><p ></p><p >
 
</p><p ><bold>IX</bold></p><p ></p><p >
 
</p><p ><bold>X</bold></p><p ></p><p ><bold>Figure 1.</bold> General formulas for the planned groups of new structures of
5-substituted 4-amino(pyrrol)3-thio-4H-1,2,4-triazoles from compounds <bold>I</bold> to <bold>X</bold></p><p >A more real possibility of a comprehensive study of
the biological activity of substances is the use of new computer prediction
technologies in silico and their
application to the assessment of the spectrum of activity of chemical compounds
with subsequent testing of the substances studied according to the results of
the prediction (Parasuraman, 2011). We have proposed a
methodology for assessing the activity using the existing calculation programs.</p><p >The logical and structural assessment of the
possible biological effect was performed using the Prediction of Activity
Spectra for Substances (PASS) computer system online (http://www.pharmaexpert.ru/PassOnline). This system predicts 565 types of the biological activity by the
structural formula of the chemical compound. These activities include the main
and side pharmacological effects, mechanisms of their implementation and toxic
manifestations, such as mutagenicity, carcinogenicity and teratogenicity (Lagunin et al., 2000).</p><p >The prediction result is presented in the form of
confidence “to be active” – Pa and “to be inactive” – Pi by the types of
activity. It should be noted that the data obtained using the PASS program can
serve only as an indicative characteristic when selecting promising molecules
and help to conduct the primary sample of probable promising groups. It is
known that the Pa value reflects, first of all, the similarity of the molecule
with the most typical known drugs of the training sample (Assyl et al., 2014).</p><p >In order to
optimize the targeted search for COX-2 inhibitors as potential antiinflammatory
agents and substantiate the feasibility of the experimental screening for the
antiinflammatory activity the docking studies were also conducted (Laube et al., 2016). Conducting the docking studies
has allowed us to investigate the affinity of a definite group of compounds to
this biological target, predict the ability of substances to inhibit the
catalytic activity of 1СХ2 and 6СОХ, i.e. to identify their inhibitor, which is
a key link in the pathogenesis of the disease. The use of in silico methods also makes it possible to save laboratory animals
in the case of complete absence of affinity to potential biological targets (Leelananda
&amp; Lindert, 2016).</p><p ><bold>Method</bold></p><p >Generation of the
3D-structure of the planned substances and their optimization using the method
of molecular mechanics MM+ and semi-empirical quantum mechanical method PM3</p><p >Objects of this
study were derivatives of
4-amino-5-(pyridine-2(3)-yl)-1,2,4-triazole(4Н)-3-yl-thioacetamides;
4-amino-5-(pyridine-4-yl)-1,2,4-triazole(4H)-3-yl-thioacetamides; and their
pyrrol derivatives of
2-((4-amino-5-(furan-2-yl)-1,2,4-triazole(4h)-3-yl)-sulfonyl)-N-acetamides and their pyrrol
derivatives, as well as the known selective COX-2 inhibitors (celecoxib, natrium
diclofenac) and non-selective inhibitor aspirin.</p><p >The choice of
antiinflammatory biological targets and determination of their active sites</p><p >Crystallographic
models of COX-2 was obtained from Protein Data Bank (www.rcsb.org), with PDB ID 6COX and PDB ID 1СХ2
(Kurumbail et al., 1997). Their difference lies in the different spatial groups of ligand
binding. In both crystallographic models of COX-2 PDB ID 1СХ2 (chains A, B, C,
D) and PDB ID 6COX (chains A, B) the following ligands were isolated: selective
COX-2 inhibitor SC-558, protoporphyrin IX (contains Fe), N-acetyl-D-glucosamine in accordance with the literature data that
1СХ2 and 6COX crystallographic models represent such spatial groups as P 21
21 2 and I 2 2 2. (Kurumbail et al., 1997). These data indicate the
difference in protein conformations, and, therefore, the structural difference
of the binding regions; it affects the protein-ligand interactions. Thus, we
considered it expedient to take into account the data obtained as a result of
the use of both crystallographic forms of COX-2 in the docking studies. After
addition hydrogen atoms to 1СХ2 and 6СОХ molecules, removal of water molecules,
and isolation of chains B, C, D and B, respectively, the active sites of
proteins 1CX2 were isolated as presented in <bold>Figure 2</bold>.</p><p ><bold>Figure 2.</bold> The active site of 1СХ2 protein</p><p >Conducting the
actual molecular docking</p><p >The docking studies of hypothetical compounds were
conducted using a SCIGRESS software package (Fujitsu, Fukuoka, Japan with license
742F6852C191). The parameter used is binding free energy (kcal/mol), where the
value of binding free energy of all test compounds is compared with comparative
compounds such as celecoxib, aspirin, and natrium diclofenac. The genetic
algorithm, an evolutionary search algorithm applied to solve optimization and
modeling problems by sequential selection, combination and variation of the
parameters studied was used for automatic docking. The use of the genetic
algorithm makes it possible to effectively study the entire available space for
the ligand (Torres et al., 2019).</p>
			</sec><sec>
			<title>RESULTS AND DISCUSSION</title>
				<p >According to the prediction results the probability
of detection of the antiinflammatory activity in the group of S-alkyl derivatives of
5-(pyridine-4-yl)-3-thio-4-amino-4Н-1,2,4-triazole (<bold>I</bold>) is insignificant, the average value of Ра does not exceed 0.39 for
the antiinflammatory activity and 0.32 for the analgesic activity. After
replacing the amino group in position 4 of the 1,2,4-triazole cycle on the
substituted benzylidene fragment an insignificant increase in the
antiinflammatory and analgesic activity of compounds in group <bold>II</bold> is predicted. After this
modification the highest probability of detection of the antiinflammatory
activity is predicted for 4-methoxy, 4-nitro, and 4-butylphenyl derivatives;
however, for these compounds, the Ра value does not exceed 0.4 for the
antiinflammatory activity and 0.49 for the analgesic activity. The average
value of Ра ≤ 0.500, hence, the group is not promising for the synthesis.</p><p >Despite the fact that the presence of a sulfonyl
group can increase the antiinflammatory activity, which has been proven in
modern COX inhibitors including piroxicam, tenoxicam, celecoxib, etc. (Cordero et al., 2001), the probability of its manifestation is insignificant according to
the results of the computer prediction for sulfonyl derivatives of
5-(pyridine-4-yl)-3-thio-4-amino-4Н-1,2,4-triazole (<bold>III</bold>). The Ра value does not exceed 0.35, in addition, there is a
clear regularity: with an increase in the number of carbon atoms in alkyl
radicals, the Ра value decreases and, therefore, there is the probability of
detecting the antiinflammatory activity. Therefore, compounds <bold>I</bold> to <bold>III</bold> were not tested by molecular docking.</p><p >With a low degree of probability (Ра ≤ 0.3), the
manifestation of the antiinflammatory activity for group <bold>IV</bold> of thiourea derivatives of
4-amino-3-thio-5-(pyridine-4-yl)-1,2,4-triazole(4Н) is predicted. According to
the data of the PASS computer program online, the antiinflammatory and
analgesic activities are predicted for those groups of compounds that contain the
pyridine cycle in position 5 (the activity indices are in the range from 0.51
to 0.66).</p><p >By the computer prediction data,
4-amino-5-(pyridine-2(3)-yl)-1,2,4-triazole(4Н)-3-yl-thioacetamides (group <bold>V</bold>) are promising compounds. Further
chemical modification by moving the nitrogen atom to the para-position of the
pyridine cycle in
4-amino-5-(pyridine-4-yl)-1,2,4-triazole(4H)-3-yl-thioacetamides – the
structure of general formula from group <bold>VI</bold>,
and the introduction of the furyl fragment (group <bold>VII</bold>) were highly appropriate. For compounds in group <bold>VII</bold>, the indices of the
antiinflammatory activity are the highest among all planned groups (0.63-0.65).
But for compounds of these groups the indices of the analgesic activity do not
significantly decrease and are in the range from 0.58 to 0.59.</p><p >Another variant of the expedient optimization was
the chemical modification of the amino group in position 4. The analysis of the
computer prediction data obtained for S-alkyl
derivatives, in which the amino group in 5-(pyridine-2,4)-4-amino
3-thio-4Н-1,2,4-triazoles (<bold>VIII</bold>-<bold>IX</bold>) and 5-(furyl-2)-4-amino
3-thio-4Н-1,2,4-triazoles (<bold>X</bold>) was
replaced by a pyrrol residue showed that the greatest probability of activity
was also at the level of approximately 60%.</p><p >Thus, according to the results of the in siliсo studies among ten planned
groups of S-derivatives of
5-(R)-4-amino-3-thio-4H-1,2,4-triazole (groups of compounds <bold>I</bold>-<bold>X</bold>),
only six groups that are likely to be antagonists of prostaglandins, and can
exhibit antiexudative and analgesic effects have been selected as promising
compounds (Chalenko &amp; Syrovaya, 2017).</p><p >The docking
studies of the sample for derivatives of 4-amino-5-(pyridine-2(3)-yl)-1,2,4-triazole(4Н)-3-yl-thioacetamides,
4-amino-5-(pyridine-4-yl)-1,2,4-triazole (4Н)-3-yl-thioacetamides and their
pyrrol derivatives,
2-((4-amino-5-(furan-2-yl)-1,2,4-triazole(4Н)-3-yl)-sulfonyl)-N-acetamides and their pyrrol
derivatives were conducted by the method of a flexible molecular docking into
the active zone of the COX-2 enzyme (Mozziconacci et al., 2005). As a result of the docking studies the value of Consensus scoring
functions, which assess certain characteristics of the ligand-protein complex
and indicate the possibility of their comparison, has been obtained. Consensus
functions allow forming a rating of compounds according to the values of all
scoring functions and analyzing data on the choice of potential
agonists/antagonists of the biological target selected (Sliwoski et al., 2014). The average values of the calculated scoring functions of molecular
docking for promising groups of compounds are given in <bold>Table I</bold>.</p><p ><bold>Table I. </bold>The values of scoring
functions for promising groups of compounds and reference drugs obtained when
conducting molecular docking</p>

<table-wrap><label>Table</label><table>
 <tr>
  <td>Compounds</td>
  
  <td>Binding free energy (kcal/mol)</td>
  
 </tr>
 <tr>
  
  <td>1CX2</td>
  
  <td>6COX</td>
  
 </tr>
 <tr>
  <td>Celecoxib</td>
  
  <td>-99.81</td>
  
  <td>-109.3</td>
  
 </tr>
 <tr>
  <td>Aspirin</td>
  
  <td>-77.7</td>
  
  <td>-79.6</td>
  
 </tr>
 <tr>
  <td>Natrium diclofenac</td>
  
  <td>-70.3</td>
  
  <td>-70.4</td>
  
 </tr>
 <tr>
  <td>IV</td>
  
  <td>-61.1 to -67.6</td>
  
  <td>-61.4 to -66.5</td>
  
 </tr>
 <tr>
  <td>V</td>
  
  <td>-91.1 to -97.6</td>
  
  <td>-91.1 to -97.6</td>
  
 </tr>
 <tr>
  <td>VI</td>
  
  <td>-108.1 to -122.7</td>
  
  <td>-108.1 to -122.7</td>
  
 </tr>
 <tr>
  <td>VII</td>
  
  <td>-98.8 to -107.67</td>
  
  <td>-98.8 to -107.67</td>
  
 </tr>
 <tr>
  <td>VIII</td>
  
  <td>-90.14 to -101.2</td>
  
  <td>-90.14 to -101.2</td>
  
 </tr>
 <tr>
  <td>IX</td>
  
  <td>-93.17 to -100.7</td>
  
  <td>-90.25 to -101.0</td>
  
 </tr>
 <tr>
  <td>X</td>
  
  <td>-87.14 to -91.2</td>
  
  <td>-87.14 to -91.2</td>
  
 </tr>
</table></table-wrap>

<p >The values of
scoring functions for almost all compounds in complexes with the COX-2 enzyme
exceed the values of these functions for aspirin and natrium diclofenac. For
group <bold>VI</bold> the average values of
scoring functions for binding free energy exceed the values for celecoxib.
Visualization of docking results for the most promising compound of group <bold>VI</bold> is presented in <bold>Figure 3</bold>.</p><p ><bold>Figure 3.</bold> The promising compound in the protein active site (1СХ2
crystallographic model)</p><p >The data obtained are an argument for studying the
antiinflammatory activity for all six groups of compounds selected. Based on
these data it has been determined that 4-amino-5-(pyridine-4-yl)-1,2,4-triazole(4Н)-3-yl-thioacetamides
and their pyrrol derivatives are characterized by the highest level of affinity
calculated to all targets studied compared with other groups of compounds.
Their affinity value is comparable to classical agonists, and it opens the
opportunity of identifying new receptor agonists. The reliability of the
prediction results has already been confirmed for one of the promising groups
4-amino-5-(pyridine-4-yl)-1,2,4-triazole(4Н)-3-yl-thioacetamides. The planned
substances have been synthesized and tested for antiinflammatory activity,
besides it has also been published scientifically (Chalenko et al., 2019).</p>
			</sec><sec>
			<title>CONCLUSION</title>
				<p >In order to search for potential antiinflammatory
agents 1,2,4-triazol-3-thiones have been selected as promising objects of
chemical modification. The strategy of rational approaches to the search for
selective COX-2 inhibitors as potential antiinflammatory agents has been
proposed and elaborated. It is based on the use of the PASS-prediction and
molecular docking. Based on the results of the PASS-prediction and molecular
docking, six of the ten planned groups of compounds have been selected for the
synthesis as promising selective COX-2 inhibitors.</p>
			</sec><sec>
			<title>ACKNOWLEDGMENT</title>
				<p >The authors gratefully acknowledge
the financial support from the National University of Pharmacy. The authors
have declared no conflict of interest.</p>
			</sec><sec>
			<title>REFERENCES</title>
				<p >Assyl, B.,
Georgiyants, V.A., &amp; Perekhoda, L.O. (2014). Study of acyl substitution on
docking properties of substituted dihydrogercetines as anti-inflammatory
agents. Journal of Chemical and
Pharmaceutical Research, 6(4), 749-753.</p><p >Cai, H.,
Huang, X., Xu, S., Shen, H., Zhang, P., Huang, Y., Jiang, J., Sun, Y., Jiang,
B., Wu, X., Yao, H., &amp; Xu, J. (2016). Discovery of novel hybrids of
diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2
and 5-lipoxygenase for cancer therapy. European
Journal of Medicinal Chemistry, 108, 89-103. doi: 10.1016/j.ejmech.2015.11.013</p><p >Chalenko,
N.M., Demchenko, A.M., &amp; Syrovaya, G.O. (2019). Synthesis and biological
activity of 4-amino-5-(pyridin-4-yl)-1,2,4-triazole(4H)-3-il-thioacetamides. Actual problems of experimental and clinical
biochemistry: materials of the international scientific-practical conference
(p. 79). Kharkiv, Ukraine: Kharkiv National Medical University.</p><p >Chalenko,
N.M. &amp; Syrovaya, G.O. (2017). The feasibility of using the prediction of
activity spectra for substances program for targeted synthesis of potential
non-steroidal class 3-thio-1,2,4-triazoles. Bioethics
and Biosafety: Multidisciplinary Aspects: Materials of a Scientific and
Practical Conference with International Participation dedicated to the 105th
Anniversary of V.K. Viskovich (pp. 160-161). Kharkiv, Ukraine: Kharkiv
National Medical University.</p><p >Cordero, J.A., Camacho, M., Obach, R., Domenech,
J., &amp; Vila, L. (2001). In vitro based index of topical anti-inflammatory
activity to compare a series of NSAIDs. European
Journal of Pharmaceutics and Biopharmaceutics, 51(2), 135-142. doi: 10.1016/s0939-6411(00)00149-1</p><p >Jiang, B.,
Zeng, Y., Li, M.J., Xu, J.Y., Zhang, Y.N., Wang, Q.J., Sun, N.Y., Lu, T., &amp;
Wu, X.M. (2010). Design, synthesis, and biological evaluation of
1,5-diaryl-1,2,4-triazole derivatives as selective cyclooxygenase-2 inhibitors.
Archiv der Pharmazie, 343(9),
500-508. doi: 10.1002/ardp.200900227</p><p >Jin, J.Y., Zhang, L.X., Zhang, A.J., Lei, X.X., &amp; Zhu, J.H. (2007).
Synthesis and Biological Activity of Some Novel Derivatives of
4-Amino-3-(D-galactopentitol-1-yl)-5-mercapto-1,2,4-triazole. Molecules, 12(8), 1596-1605. doi: 10.3390/12081596</p><p >Khanage,
S.G., Raju, S.A., Mohite, P.B., &amp; Pandhare, R.B. (2012). Synthesis and
Pharmacological Evaluation of Some New Pyrimidine Derivatives Containing
1,2,4-Triazole. Advanced Pharmaceutical
Bulletin, 2(2), 213-222. doi: 10.5681/apb.2012.033</p><p >Kurumbail, R.G., Stevens, A.M., Gierse, J.K., McDonald, J.J., Stegeman,
R.A., Pak, J.Y., Gildehaus, D., Miyashiro, J.M., Penning, T.D., Seibert, K.,
Isakson, P.C., &amp; Stallings, W.C. (1997). Correction: Structural basis for
selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature, 385, 555. doi: 10.1038/385555b0</p><p >Lagunin, A.,
Stepanchikova, A., Filimonov, D., &amp; Poroikov, V. (2000). PASS: prediction
of activity spectra for biologically active substances. Bioinformatics, 16(8), 747-748. doi: 10.1093/bioinformatics/16.8.747</p><p >Laube, M., Kniess, T., &amp; Pietzsch, J.
(2016). Development of Antioxidant COX-2 Inhibitors as Radioprotective Agents
for Radiation Therapy—A Hypothesis-Driven Review. Antioxidants, 5(2), 14. doi: 10.3390/antiox5020014</p><p >Leelananda,
S.P. &amp; Lindert, S. (2016). Computational methods in drug discovery. Beilstein Journal of Organic Chemistry, 12,
2694-2718. doi: 10.3762/bjoc.12.267</p><p >Mioc, M., Soica, C., Bercean, V., Avram, S.,
Balan-Porcarasu, M., Coricovac, D., Ghiulai, R., Muntean, D., Andrica, F.,
Dehelean, C., Spandidos, D.A., Tsatsakis, A.M., &amp; Kurunczi, L. (2017).
Design, synthesis and pharmaco-toxicological assessment of
5-mercapto-1,2,4-triazole derivatives with antibacterial and antiproliferative
activity. International Journal of
Oncology, 50(4), 1175-1183. doi: 10.3892/ijo.2017.3912</p><p >Moise, M., Sunel, V., Profire, L., Popa, M., Desbrieres, J., &amp;
Peptu, C. (2009). Synthesis and Biological Activity of Some New
1,3,4-Thiadiazole and 1,2,4-Triazole Compounds Containing a Phenylalanine
Moiety. Molecules, 14(7), 2621-2631. doi: 10.3390/molecules14072621</p><p >Mozziconacci, J.C., Arnoult, E., Bernard, P., Do, Q.T., Marot, C., &amp;
Morin-Allory, L. (2005). Optimization and validation of a docking-scoring
protocol; application to virtual screening for COX-2 inhibitors. Journal of Medicinal Chemistry, 48(4),
1055-1068. doi: 10.1021/jm049332v</p><p >Oliveira, J.W.F., Rocha, H.A.O., de Medeiros, W.M.T.Q., &amp; Silva,
M.S. (2019). Application of Dithiocarbamates as Potential New
Antitrypanosomatids-Drugs: Approach Chemistry, Functional and Biological. Molecules, 24(15), 2806. doi: 10.3390/molecules24152806</p><p >Parasuraman, S. (2011). Prediction of activity spectra for substances. Journal of Pharmacology and
Pharmacotherapeutics, 2(1), 52-53. doi: 10.4103/0976-500X.77119</p><p >Sliwoski, G., Kothiwale, S., Meiler, J., &amp;
Lowe Jr., E.W. (2014). Computational Methods in Drug Discovery. Pharmacological Reviews, 66(1), 334-395. doi: 10.1124/pr.112.007336</p><p >Sondhi, S.M., Dinodia, M., Singh, J., &amp;
Rani, R. (2007). Heterocyclic Compounds as Anti-Inflammatory Agents. Current Bioactive Compounds, 3(2),
91-108. doi: 10.2174/157340707780809554</p><p >Torres, P.H.M., Sodero, A.C.R., Jofily, P., &amp; Silva Jr., F.P.
(2019). Key Topics in Molecular Docking for Drug Design. International Journal of Molecular Sciences, 20(18), 4574. doi: 10.3390/ijms20184574</p><p >Zhuang, C.,
Zhang, W., Sheng, C., Zhang, W., Xing, C., &amp; Miao, Z. (2017). Chalcone: A
Privileged Structure in Medicinal Chemistry. Chemical Reviews, 117(12), 7762-7810. doi: 10.1021/acs.chemrev.7b00020</p>
			</sec></body>
  <back>
    <ack>
      <p>The authors gratefully acknowledge the financial support from the National University of Pharmacy. The authors have declared no conflict of interest.</p>
    </ack>
  </back>
</article>